Market cap of Lixte Biotechnology Holdings Inc. [LIXT] reaches 20.15M – now what?

Related

Lixte Biotechnology Holdings Inc. [NASDAQ: LIXT] stock went on an upward path that rose over 3.51% on Thursday, amounting to a one-week price decrease of less than -1.67%. The company report on April 14, 2022 that LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $5.8 million of common stock. The Company issued a total of 2,900,000 shares of common stock at a purchase price of $2.00 per share.

WestPark Capital, Inc. and WallachBeth Capital, LLC acted as co-placement agents for the offering.

Over the last 12 months, LIXT stock dropped by -59.17%.

The market cap for the stock reached $20.15 million, with 13.75 million shares outstanding and 8.72 million shares in the current float. Compared to the average trading volume of 3.34M shares, LIXT stock reached a trading volume of 2949381 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Lixte Biotechnology Holdings Inc. [LIXT]:

The Average True Range (ATR) for Lixte Biotechnology Holdings Inc. is set at 0.26 The Price to Book ratio for the last quarter was 13.11, with the Price to Cash per share for the same quarter was set at 0.28.

LIXT Stock Performance Analysis:

Lixte Biotechnology Holdings Inc. [LIXT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.67. With this latest performance, LIXT shares dropped by -3.28% in over the last four-week period, additionally sinking by -41.29% over the last 6 months – not to mention a drop of -59.17% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LIXT stock in for the last two-week period is set at 45.40, with the RSI for the last a single of trading hit 43.95, and the three-weeks RSI is set at 45.90 for Lixte Biotechnology Holdings Inc. [LIXT]. The present Moving Average for the last 50 days of trading for this stock 1.3134, while it was recorded at 1.1720 for the last single week of trading, and 1.8220 for the last 200 days.

Insight into Lixte Biotechnology Holdings Inc. Fundamentals:

Return on Equity for this stock declined to -137.28, with Return on Assets sitting at -130.37.

Lixte Biotechnology Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.80 and a Current Ratio set at 16.80.

Lixte Biotechnology Holdings Inc. [LIXT] Insider Position Details

There are presently around $1 million, or 7.30% of LIXT stock, in the hands of institutional investors. The top three institutional holders of LIXT stocks are: ALMANACK INVESTMENT PARTNERS, LLC. with ownership of 779,084, which is approximately -3.345% of the company’s market cap and around 2.20% of the total institutional ownership; SANTA MONICA PARTNERS LP, holding 166,667 shares of the stock with an approximate value of $0.2 million in LIXT stocks shares; and VANGUARD GROUP INC, currently with $91000.0 in LIXT stock with ownership of nearly -0.958% of the company’s market capitalization.

6 institutional holders increased their position in Lixte Biotechnology Holdings Inc. [NASDAQ:LIXT] by around 24,938 shares. Additionally, 2 investors decreased positions by around 27,713 shares, while 3 investors held positions by with 1,156,731 shares. The mentioned changes placed institutional holdings at 1,209,382 shares, according to the latest SEC report filing. LIXT stock had 1 new institutional investments in for a total of 14,165 shares, while 0 institutional investors sold positions of 0 shares during the same period.